Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Usage of eltrombopag for chronic immune thrombocytopenia as a pretreatment for splenectomy.

Uwagawa T, Misawa T, Furukawa K, Ito R, Futagawa Y, Yahagi Y, Aiba K, Yanaga K.

Acta Haematol. 2013;129(1):45-7. doi: 10.1159/000342105. Epub 2012 Oct 31. No abstract available.

PMID:
23128016
2.

Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.

Scheinberg P, Singulane CC, Barbosa LS, Scheinberg M.

Clin Rheumatol. 2014 Sep;33(9):1347-9. doi: 10.1007/s10067-014-2600-8. Epub 2014 Apr 17.

PMID:
24740463
3.

Thrombopoietin-receptor agonists for primary immune thrombocytopenia.

Imbach P, Crowther M.

N Engl J Med. 2011 Aug 25;365(8):734-41. doi: 10.1056/NEJMct1014202. Review. No abstract available.

PMID:
21864167
4.

Eltrombopag in chronic hepatitis C.

Mihăilă RG, Cipăian RC.

World J Gastroenterol. 2014 Sep 21;20(35):12517-21. doi: 10.3748/wjg.v20.i35.12517. Review.

5.

Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.

Modi Y, Shaaban H, Gauchan D, Maroules M.

J Oncol Pharm Pract. 2015 Feb;21(1):74-5. doi: 10.1177/1078155214544076. Epub 2014 Jul 24.

PMID:
25063763
6.

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.

Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB.

Lancet. 2011 Jan 29;377(9763):393-402. doi: 10.1016/S0140-6736(10)60959-2. Epub 2010 Aug 23. Erratum in: Lancet. 2011 Jan 29;377(9763):382.

PMID:
20739054
7.

Eltrombopag in thrombocytopenia.

Lawson A.

N Engl J Med. 2008 Mar 6;358(10):1072; author reply 1072-3. doi: 10.1056/NEJMc073571. No abstract available.

8.

Eltrombopag for the treatment of immune thrombocytopenia.

Cheng G.

Expert Rev Hematol. 2011 Jun;4(3):261-9. doi: 10.1586/ehm.11.25.

PMID:
21671710
9.

Current status of thrombopoietic agents.

Rhodes E, Stasi R.

Expert Rev Hematol. 2010 Apr;3(2):217-25. doi: 10.1586/ehm.10.8. Review.

PMID:
21083464
10.

[New treatment options for primary immune thrombocytopenia].

Gudbrandsdottir S, Frederiksen H, Birgens HS, Nielsen CH, Nielsen OJ, Stentoft J, Hasselbalch HC.

Ugeskr Laeger. 2011 Jan 24;173(4):271-4. Danish.

PMID:
21262171
11.

Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.

Gauchan D, Shaaban H, Gedeon D, Maroules M.

Ann Hematol. 2014 Oct;93(10):1777-8. doi: 10.1007/s00277-014-2032-1. Epub 2014 Feb 20. No abstract available.

PMID:
24554304
12.

Eltrombopag for chronic immune thrombocytopenia.

Milosevic I, Slade E, Drysdale H; COMPare project team.

Lancet. 2016 Jan 23;387(10016):336. doi: 10.1016/S0140-6736(16)00107-0. No abstract available.

PMID:
26842445
13.

Molecule of the month. Eltrombopag.

[No authors listed]

Drug News Perspect. 2008 Jul-Aug;21(6):344. No abstract available.

PMID:
18836592
14.

Eltrombopag for chronic immune thrombocytopenia - Authors' reply.

Grainger JD; PETIT2 authors.

Lancet. 2016 Jan 23;387(10016):336-337. doi: 10.1016/S0140-6736(16)00009-X. No abstract available.

PMID:
26842444
15.

What is publication? The case of eltrombopag.

Benham L, Guo L, Turner R.

Lancet. 2011 Jan 29;377(9763):360-1. doi: 10.1016/S0140-6736(11)60024-X. No abstract available.

PMID:
21277427
16.

Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia.

Trautmann K, Jakob C, von Grünhagen U, Schleyer E, Brümmendorf TH, Siegert G, Ehninger G, Platzbecker U.

Thromb Haemost. 2012 Aug;108(2):397-8. doi: 10.1160/TH12-02-0121. Epub 2012 Jun 28. No abstract available.

PMID:
22739569
17.

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.

Violi F, Pignatelli P.

N Engl J Med. 2012 Nov 22;367(21):2056. doi: 10.1056/NEJMc1211471#SA2. No abstract available.

PMID:
23171115
18.

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.

Lisman T, Porte RJ.

N Engl J Med. 2012 Nov 22;367(21):2055-6. doi: 10.1056/NEJMc1211471#SA1. No abstract available.

PMID:
23171114
19.

Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.

Polverelli N, Palandri F, Iacobucci I, Catani L, Martinelli G, Vianelli N.

Br J Haematol. 2013 Apr;161(1):142-4. doi: 10.1111/bjh.12186. Epub 2012 Dec 29. No abstract available.

PMID:
23278214
20.

Eltrombopag for treatment of thrombocytopenia-associated disorders.

Merli P, Strocchio L, Vinti L, Palumbo G, Locatelli F.

Expert Opin Pharmacother. 2015;16(14):2243-56. doi: 10.1517/14656566.2015.1085512. Review.

PMID:
26364898

Supplemental Content

Support Center